Blood
Articles in this Issue
Study design of A phase 3, open-label trial for pozelimab and cemdisiran combination therapy in patients with paroxysmal nocturnal hemoglobinuria with inadequate control of intravascular hemolysis
Abstract Background and significance: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, life-threatening disease, characterized by comple...
Fludarabine and total body irradiation 800 cgy or 1125 cgy for allogeneic stem cell transplant using graft versus host disease prophylaxis with post-transplant cyclophosphamide and tacrolimus, without mycophenolate mofetil (OmitMMF trial)
Abstract Background: Mycophenolate mofetil (MMF) has been a standard adjunct of the post-transplant cyclophosphamide (PT...
Peripheral blood plasma proteomics reveals dysregulated cholesterol transport and complement pathways in myeloproliferative neoplasms
Abstract Myeloproliferative neoplasms (MPNs) are rare, age-related hematologic malignancies characterized by the clonal expansion of myeloid...
AI-powered leukemia intelligent virtual examiner (LIVE) for rapid and accurate diagnosis of acute lymphoblastic leukemia
Abstract Background: Acute lymphoblastic leukemia (ALL) is a hematological malignancy characterized by clonal proliferation of immature lymp...
Response-adapted treatment with mosunetuzumab with or without obinutuzumab and polatuzumab vedotin in treatment naïve follicular and marginal zone lymphoma: Final results and phased-seq MRD analysis
Abstract Background: Mosunetuzumab (mosun) is a CD20xCD3 bispecific antibody that is active in relapsed/refractory follicular lymphoma. We de...
Highly efficient collection and manufacture of autologous HSC gene therapy cell product for patients with sickle cell disease using a lentiviral vector containing a shmir targeting BCL11a
Abstract Achieving an adequate dose of genetically modified hematopoietic stem cells (HSCs) for gene therapy in patients with sickle cell di...
FLT3-ITD NGS-MRD refines risk stratification in NPM1 and FLT3 co-mutated AML beyond NPM1 PCR-MRD: Analysis of the UK NCRI AML17 and AML19 trials
Abstract Introduction In NPM1 mutant AML, detection of measurable residual disease by reverse transcription quantitative PCR (hereafter, NPM...
The radiofrequency therapy in management of sickle cell disease chronic pain
Abstract Sickle cell disease causes acute and chronic pain. Pain causes significant morbidity for those living with sickle cell disease (SCD...
Attention-based multiple instance learning predicts CAR T cell therapy outcomes from infusion product single-cell RNA-seq data and identifies engineering targets in large B cell lymphoma
Abstract Chimeric antigen receptor (CAR) T cell therapies have revolutionized treatment for hematological malignancies, yet over 50% of pati...
Blinatumomab following reduced-intensity induction chemotherapy in Chinese children with intermediate- or high-risk B-cell precursor acute lymphoblastic leukemia
Abstract Background Minimal residual disease (MRD) level after induction therapy is a key independent prognostic factor in pediatric B-cell...
R-mini-CHOP preserves efficacy and limits toxicity for patients ≥ 80 years old with DLBCL
Abstract Introduction: More than half of patients (pts) diagnosed with diffuse large B-cell lymphoma (DLBCL) are diagnosed at the age of 65...
Trends in cardiovascular eligibility criteria in clinical trials of hematologic malignancies: a 20-year analysis
Abstract Background Patients with hematologic malignancies frequently have co-existing cardiovascular disease (CVD) that is either de-novo o...
Loss of serine threonine protein kinase 25 (STK25) in the bone marrow niche attenuates g/CSF- and TLR7-induced emergency myelopoiesis and mobilization into the periphery
Abstract Introduction. Inflammation is the immune system's response to harmful stimuli, such as pathogen-associated molecular patterns (PAMP...
Hepatic stellate cell activation leads to impaired ADAMTS13 secretion and VWF/ADAMTS13 imbalance in liver cirrhosis
Abstract Background: The coagulopathy of liver cirrhosis remains incompletely understood. Intrahepatic microthrombi formation is integral to...
Adult Acute Myeloid Leukemia with fus::ERG fusion: A national, retrospective, multi-center study
Abstract Introduction: Acute myeloid leukemia (AML) with t(16;21)(p11;q22)/FUS::ERG demonstrate poor outcomes even after allogeneic hematopo...
A tandem bispecific nanobody CAR (SL1703) T cells targeting CD19/BCMA for refractory or relapsed multiple myeloma as salvage treatment after BCMA CAR-T therapy failure
Abstract Background: Despite that high response rate induced by BCMA chimeric antigen receptor T-cell therapy (CAR-T) in relapsed or refract...
Siltuximab versus tocilizumab for the management of CAR T-cell associated cytokine release syndrome
Abstract Background Chimeric antigen receptor (CAR) T-cell therapy is a promising treatment for hematological malignancies but is associated...
autologous hematopoietic cell transplantation (AHCT) in the era of novel therapies for multiple myeloma– real-world data from a single cente
Abstract Introduction Despite the tremendous improvement in the treatment landscape of multiple myeloma (MM) patients, a...
Respiratory syncytial virus (RSV) infection after CAR T-cell therapy
Abstract Background: Respiratory syncytial virus (RSV) is a recognized cause of morbidity and mortality after allogeneic HCT (allo-HCT), but...
TPO-ras for persistent thrombocytopenia following CAR-T therapy in multiple myeloma: A multicenter clinical experience
Abstract Introduction: While chimeric antigen receptor T (CAR-T) cell therapies demonstrated significant efficacy in mul...
Long-term follow-up of patients with aplastic anemia enrolled in two phase 2/3 trials of immunosuppressive therapy plus romiplostim as a first-line treatment: Final report for up to 5 years
Abstract Background Results from two phase 2/3 clinical trials evaluating the safety and efficacy of immunosuppressive therapy (IST) plus rom...
Deep responses and durable outcomes in patients treated with belantamab mafodotin plus pomalidomide and dexamethasone from long-term follow-up of the Phase 3 dreamm-8 study
Abstract Introduction: Triplet or quadruplet regimens, combining proteasome inhibitors, immunomodulators, and anti-CD38 monoclonal antibodie...
The first integrated proteomic and lipidomic profiling reveals immune, metabolic, and membrane remodeling signatures in patients experiencing cytokine release storm (CRS) undergoing CAR-T cell therapy and serves as a new predictive and prognostic factor.
Abstract Background: Cytokine release syndrome (CRS) is a common and potentially life-threatening complication following chimeric antigen rec...
Outcomes with itacitinib prophylaxis for cytokine release syndrome: A systematic review
Abstract Introduction: Cytokine release syndrome (CRS) is a common and severe adverse effect reported with many chemotherapeutic agents, cel...
Validation of blast and blast-mol risk models in chronic myelomonocytic leukemia: Mayo-humanitas collaborative project involving 1,101 patients
Abstract Background: The recently published BLAST clinical and BLAST molecular (BLAST-Mol) risk models for chronic myelomonocytic leukemia (...